Prothena Reports U.S. Food and Drug Administration Grants Fast Track Status to Coramitug (PRX004) for ATTR Cardiomyopathy, Secured by Novo Nordisk
Prothena Corporation plc has announced a key regulatory development for coramitug, an investigational therapy being advanced for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The U.S. Food and Drug Administration has granted Fast Track Designation to coramitug, a move intended to accelerate the development and review of therapies that address serious conditions and fulfill significant unmet medical needs.
Coramitug, currently in Phase 3 clinical development, is being advanced by Novo Nordisk, which holds global rights to the therapy following its acquisition of Prothena’s ATTR amyloidosis business in 2021. The Fast Track Designation highlights both the urgency of addressing ATTR-CM and the potential of coramitug to offer a meaningful therapeutic advancement for patients living with this progressive and life-threatening disease.
ATTR-CM is a condition characterized by the accumulation of misfolded transthyretin proteins in the heart muscle, forming amyloid deposits that impair cardiac function. Over time, these deposits lead to stiffening of the heart, reduced pumping efficiency, and ultimately heart failure. While existing treatments can help stabilize transthyretin and slow disease progression, they do not effectively remove the amyloid deposits that have already accumulated. This limitation underscores the need for therapies that can actively clear these deposits and potentially improve cardiac function.
Coramitug is designed to address this gap through a novel mechanism of action. As a humanized monoclonal antibody, it specifically targets misfolded transthyretin proteins within amyloid deposits. By binding to these abnormal proteins, coramitug is intended to trigger antibody-mediated phagocytosis, a process by which immune cells recognize and remove harmful पदार्थ from the body. This amyloid-clearing approach positions coramitug as a potential best-in-class therapy, with the ability not only to halt disease progression but also to reverse some of the underlying pathology.
The FDA’s Fast Track Designation is a significant milestone in the development pathway for coramitug. This designation is reserved for investigational therapies that demonstrate the potential to address serious conditions where there is a clear unmet need. It provides several advantages, including more frequent interactions with the FDA, eligibility for accelerated approval pathways, and the possibility of rolling review of regulatory submissions. Collectively, these benefits can help bring promising therapies to patients more quickly.
Executives from both Prothena and Novo Nordisk emphasized the importance of this recognition. Gene Kinney, President and CEO of Prothena, noted that the designation reflects Novo Nordisk’s continued commitment to advancing coramitug for patients with ATTR-CM. Although Prothena is no longer directly leading the clinical development of the therapy, it retains a financial interest through milestone payments tied to the program’s progress.
Michelle Lim-Watson, Associate Portfolio Vice President for Cardiovascular and Rare Diseases at Novo Nordisk’s U.S. R&D division, highlighted the broader implications of the designation. She აღნიშნა that ATTR-CM remains a serious and under-addressed condition despite the availability of current therapies, and that coramitug has the potential to represent a meaningful step forward in treatment. The Fast Track status, she noted, underscores both the severity of the disease and the need for innovative therapeutic approaches.
Coramitug is currently being evaluated in the ongoing Phase 3 CLEOPATTRA clinical trial, a large-scale, global study designed to assess its safety and efficacy in approximately 1,280 patients with ATTR-CM. The trial is expected to reach primary completion in 2029, reflecting the complexity and long-term nature of studying outcomes in this patient population. The results of this study will be critical in determining whether coramitug can fulfill its promise as a disease-modifying therapy.
The collaboration between Prothena and Novo Nordisk has played a central role in advancing this program. In July 2021, Novo Nordisk acquired full worldwide rights to Prothena’s ATTR amyloidosis portfolio, including coramitug. Under the terms of the agreement, Prothena is eligible to receive up to $1.2 billion in total payments, including upfront compensation and additional milestones tied to clinical development and commercial success. To date, Prothena has received $150 million, reflecting progress in the program’s development.
The development of coramitug also reflects broader trends in the treatment of amyloid diseases, where there is increasing focus on therapies that can directly target and remove pathogenic protein aggregates. Similar approaches are being explored in other conditions, including neurodegenerative diseases, highlighting the growing importance of antibody-based therapies in addressing complex protein misfolding disorders.
For patients with ATTR-CM, the potential impact of such therapies is significant. The disease often goes underdiagnosed or misdiagnosed, and once identified, treatment options have historically been limited. The ability to not only slow disease progression but also reduce or eliminate existing amyloid deposits could represent a transformative advance in patient care.
In summary, the FDA’s Fast Track Designation for coramitug marks an important step forward in the effort to develop more effective treatments for ATTR-CM. By enabling a more streamlined development and review process, the designation supports the continued advancement of a therapy that has the potential to address a critical unmet need. As the Phase 3 CLEOPATTRA trial progresses, stakeholders across the healthcare community will be closely watching for data that could pave the way for a new standard of care in this challenging disease area.
About Coramitug (PRX004)
Coramitug is an investigational antibody designed to deplete amyloid associated with disease pathology in hereditary and wild type ATTR amyloidosis, without affecting the native, normal tetrameric form of the protein1-3. Coramitug’s proposed mechanism of action is to deplete both the deposited amyloid to improve organ function and circulating non-native TTR to prevent further organ deposition1-3. This differentiated depleter mechanism of action could be developed as a monotherapy approach to ATTR amyloidosis and might also complement existing therapeutic approaches which either stabilize or reduce production of the native TTR tetramer3.
In a Phase 2 clinical trial conducted by Novo Nordisk, coramitug 60 mg/kg significantly reduced and improved NT-proBNP from baseline, in a patient population in which the vast majority (>80%) were already receiving standard of care treatment for ATTR-CM. Furthermore, compared with placebo, coramitug was associated with improvements in multiple echocardiographic parameters of cardiac function, and was well-tolerated in participants with ATTR-CM. These findings support the potential of coramitug as an amyloid-clearing immunotherapy for ATTR-CM and provide a rationale for additional clinical investigation of coramitug for the treatment of patients with ATTR-CM4.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged.
Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying CYTOPE®, a novel technology that incorporates a cell-internalizing domain to drive efficient cytosolic delivery with highly specific marcomolecular effectors.
Source Link:https://www.businesswire.com/
